Program
Influenza virus split vaccine (0.7mL/vial)
Its studies are mostly in Influenza, Human, led by Sinopharm.
Furthest: phase 2, since Dec 25, 20252 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinopharm | 22 open or running | phase 2since Dec 25, 2025 | Dec 11, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2025First study: phase 1 study in Influenza, HumanFirst studyNCT07302256 · 120 planned · China
- Dec 25, 2025Phase 2 study in Influenza, HumanPhase 2 reachedNCT07327398 · 1,200 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Influenza virus split vaccine (0.7mL/vial)”name, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07327398Influenza, Human · China | 2 | Not yet recruiting | Sep 30, 2026 | 1,200 |
| NCT07302256Influenza, Human · China | 1 | Recruiting | Aug 31, 2026 | 120 |
How it is read
Names in the registry
- “Influenza virus split vaccine (0.7mL/vial)”, 2 entries
Conditions, from the studies’ own filings
- Influenza, Human, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.